Sarcoma and Cutaneous Tumors

PV QA 2 - Poster Viewing Q&A 2

MO_21_2692 - Radiation Therapy in Intrathoracic Sarcomas. A Rare Cancer Network Study

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Radiation Therapy in Intrathoracic Sarcomas. A Rare Cancer Network Study
F. Larsen1, P. Sargos2, V. Linacre3, F. Suarez4, M. Terlizzi2, Y. Kirova5, P. J. Van Houtte6, D. Lerouge7, and C. V. Sole1; 1Clinica IRAM, Santiago, Chile, 2Department of Radiation Oncology. Institut Bergonie, Bordeaux, France, 3Instituto Nacional del Torax, Santiago, Chile, 4Clinica Santa Maria, Santiago, Chile, 5Institut Curie, Paris, France, 6Institut Bordet, Bruxelles, Belgium, 7Department of Radiation Oncology. Centre Baclesse, Caen, France

Purpose/Objective(s): Intrathoracic sarcomas (ITS) are considered rare tumors and have a dismal prognosis. We investigated outcomes and risk factors for local control (LC) and overall survival (OS) in patients with non-metastatic ITS treated with curative intent. The hypothesis is that radiotherapy (RT) is associated with higher OS.

Materials/Methods: Patients from the Rare Cancer Network database were studied. Kaplan Meier estimate was used to assess survival curves and Cox proportional hazards regression was used to assess risk factors for LC and OS.

Results: Between 2000 and 2017, 139 patients met inclusion criteria. Primary site was lung in 41%, mediastinum 36% and pleura in 23%. Grade was 1, 2, and 3 in 9%, 43%, and 48%; respectively. ITS was synovial, liposarcoma, leiomiosarcoma, undifferentiated pleomorphic, and other in 23%, 22%, 14%, 13%, and 28%; respectively. Surgery was performed in 74% (58 % R0), RT (median dose, 50.4 Gy) was performed in 44 (32%) patients and 67 (48%) patients had adjuvant chemotherapy. Median follow-up was 42.6 months (range, 2-141), there were 94 (68%) relapses including 55 local and 39 distant relapses. Five year LC and OS was 43 and 34%. In multivariate analysis R0 resection [HR 0.40 (0.24-0.67), p <0.01], and RT [HR 0.47 (0.24-0.91), p = 0.02] remained associated with a decreased risk of death. Late grade 3 toxicity was noted in 7 patients.

Conclusion: This joint analysis revealed that OS remains modest, mainly given by the high risk of local failure. Our results suggest that this group can benefit from RT.

Author Disclosure: F. Larsen: None. V. Linacre: None. M. Terlizzi: None. P.J. Van Houtte: None.

Francisco Larsen, MD

Presentation(s):

Send Email for Francisco Larsen


Assets

MO_21_2692 - Radiation Therapy in Intrathoracic Sarcomas. A Rare Cancer Network Study



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Radiation Therapy in Intrathoracic Sarcomas. A Rare Cancer Network Study